T세포 혈액암 : 시장 인사이트, 역학 및 시장 예측(-2034년)

T-Cell Blood Cancer - Market Insight, Epidemiology, and Market Forecast - 2034

US $ 7,950 ￦ 11,458,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,925 ￦ 17,187,000

PDF (2-3 User License)

PDF 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 15,900 ￦ 22,916,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 23,850 ￦ 34,375,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

이 보고서는 미국, 독일, 스페인, 이탈리아, 프랑스, 영국, 일본, 독일, 스페인, 이탈리아, 프랑스, 영국, 일본 등 7개 주요 T세포 혈액암 시장을 조사 분석하여 각 지역 시장 규모, 현재 치료법, 미충족 수요, 새로운 치료법 등에 대한 정보를 제공합니다.

목차

제1장 프리미엄 인사이트

제2장 T세포 혈액암 주요 요약

제3장 T세포 혈액암 경쟁 정보 분석

제4장 T세포 혈액암 : 시장 개요

• T세포 혈액암 전체 시장 점유율 분포(2020년)
• T세포 혈액암 전체 시장 점유율 분포(2034년)

제5장 T세포 혈액암 : 질환 배경과 개요

• 서론
• 징후와 증상
• 병태생리학
• 위험 요인
• 진단

제6장 환자 여정

제7장 T세포 혈액암의 역학과 환자 인구

• 역학 주요 조사 결과
• 전제조건과 근거 : 주요 7개 시장
• 역학 시나리오 : 주요 7개 시장
  • 주요 7개 시장의 T세포 혈액암 역학 시나리오(2020-2034년)
• 미국의 역학
  • 미국의 T세포 혈액암 역학 시나리오(2020-2034년)
• 유럽 5개국의 역학 : 국가별
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국
  • 일본

제8장 치료 알고리즘, 현재 치료, 의료 행위

• T세포 혈액암 치료와 관리
• T세포 혈액암 치료 알고리즘

제9장 미충족 요구

제10장 T세포 혈액암 치료의 주요 평가항목

제11장 출시 제품

제12장 새로운 치료법

제13장 T세포 혈액암 : 주요 7개 시장 분석

• 주요 조사 결과
• 주요 7개 시장 T세포 혈액암 시장 규모
• 주요 7개 시장 T세포 혈액암 시장 규모 : 치료법별

제14장 속성 분석

제15장 주요 7개 시장 : 시장 전망

• 미국 : 시장 규모
  • 미국의 T세포 혈액암 전체 시장 규모
  • 미국의 T세포 혈액암 시장 규모 : 치료법별
• 유럽 5개국 : 시장 규모와 전망
• 독일 : 시장 규모
  • 독일의 T세포 혈액암 전체 시장 규모
  • 독일의 T세포 혈액암 시장 규모 : 치료법별
• 프랑스 시장 규모
• 이탈리아 시장 규모
• 스페인 시장 규모
• 영국 : 시장 규모
  • 영국의 T세포 혈액암 전체 시장 규모
  • 영국의 T세포 혈액암 시장 규모 : 치료법별
• 일본 시장 전망
  • 일본 시장 규모

제16장 T세포 혈액암 접근 및 상환 개요

제17장 KOL(Key Opinion Leader)의 견해

제18장 시장 성장 촉진요인

제19장 시장 장벽

제20장 부록

제21장 DelveInsight의 서비스 내용

제22장 면책사항

제23장 DelveInsight에 대해

LSH

영문 목차

영문목차

DelveInsight's "T-Cell Blood Cancer - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the T-Cell Blood Cancer, historical and forecasted epidemiology as well as the T-Cell Blood Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The T-Cell Blood Cancer market report provides current treatment practices, emerging drugs, T-Cell Blood Cancer market share of the individual therapies, current and forecasted T-Cell Blood Cancer market size from 2020 to 2034 segmented by seven major markets. The Report also covers current T-Cell Blood Cancer treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2020-2034

T-Cell Blood Cancer Disease Understanding and Treatment Algorithm

The DelveInsight T-Cell Blood Cancer market report gives a thorough understanding of the T-Cell Blood Cancer by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for T-Cell Blood Cancer.

Treatment

It covers the details of conventional and current medical therapies available in the T-Cell Blood Cancer market for the treatment of the condition. It also provides T-Cell Blood Cancer treatment algorithms and guidelines in the United States, Europe, and Japan.

T-Cell Blood Cancer Epidemiology

The T-Cell Blood Cancer epidemiology division provide insights about historical and current T-Cell Blood Cancer patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted T-Cell Blood Cancer epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-T-Cell Blood Cancer Epidemiology

The epidemiology segment also provides the T-Cell Blood Cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

T-Cell Blood Cancer Drug Chapters

Drug chapter segment of the T-Cell Blood Cancer report encloses the detailed analysis of T-Cell Blood Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the T-Cell Blood Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for T-Cell Blood Cancer treatment.

T-Cell Blood Cancer Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for T-Cell Blood Cancer treatment.

T-Cell Blood Cancer Market Outlook

The T-Cell Blood Cancer market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted T-Cell Blood Cancer market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of T-Cell Blood Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, T-Cell Blood Cancer market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the T-Cell Blood Cancer market in 7MM.

The United States Market Outlook

This section provides the total T-Cell Blood Cancer market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total T-Cell Blood Cancer market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total T-Cell Blood Cancer market size and market size by therapies in Japan is also mentioned.

T-Cell Blood Cancer Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the T-Cell Blood Cancer market or expected to get launched in the market during the study period 2020-2034. The analysis covers T-Cell Blood Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

T-Cell Blood Cancer Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses T-Cell Blood Cancer key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for T-Cell Blood Cancer emerging therapies.

Reimbursement Scenario in T-Cell Blood Cancer

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in T-Cell Blood Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or T-Cell Blood Cancer market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the T-Cell Blood Cancer Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of T-Cell Blood Cancer, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the T-Cell Blood Cancer epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for T-Cell Blood Cancer are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of T-Cell Blood Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global T-Cell Blood Cancer market

Report Highlights:

• In the coming years, T-Cell Blood Cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence T-Cell Blood Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for T-Cell Blood Cancer. Launch of emerging therapies will significantly impact the T-Cell Blood Cancer market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for T-Cell Blood Cancer
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

T-Cell Blood Cancer Report Insights

• Patient Population
• Therapeutic Approaches
• T-Cell Blood Cancer Pipeline Analysis
• T-Cell Blood Cancer Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

T-Cell Blood Cancer Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• T-Cell Blood Cancer Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

T-Cell Blood Cancer Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions:

Market Insights:

• What was the T-Cell Blood Cancer market share (%) distribution in 2020 and how it would look like in 2034?
• What would be the T-Cell Blood Cancer total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest T-Cell Blood Cancer market size during the forecast period (2024-2034)?
• At what CAGR, the T-Cell Blood Cancer market is expected to grow in 7MM during the forecast period (2020-2034)?
• What would be the T-Cell Blood Cancer market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the T-Cell Blood Cancer market growth till 2032, and what will be the resultant market Size in the year 2034?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of the T-Cell Blood Cancer?
• What is the historical T-Cell Blood Cancer patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of T-Cell Blood Cancer in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to T-Cell Blood Cancer?
• Out of all 7MM countries, which country would have the highest prevalent population of T-Cell Blood Cancer during the forecast period (2020-2034)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the T-Cell Blood Cancer treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of T-Cell Blood Cancer in the USA, Europe, and Japan?
• What are the T-Cell Blood Cancer marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of T-Cell Blood Cancer?
• How many therapies are developed by each company for T-Cell Blood Cancer treatment?
• How many are emerging therapies in mid-stage, and late stage of development for T-Cell Blood Cancer treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the T-Cell Blood Cancer therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for T-Cell Blood Cancer and their status?
• What are the key designations that have been granted for the emerging therapies for T-Cell Blood Cancer?
• What are the global historical and forecasted market of T-Cell Blood Cancer?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the T-Cell Blood Cancer market
• To understand the future market competition in the T-Cell Blood Cancer market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for T-Cell Blood Cancer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for T-Cell Blood Cancer market
• To understand the future market competition in the T-Cell Blood Cancer market

Table of Contents

1. Key Insights

2. Executive Summary of T-Cell Blood Cancer

3. Competitive Intelligence Analysis for T-Cell Blood Cancer

4. T-Cell Blood Cancer: Market Overview at a Glance

• 4.1. T-Cell Blood Cancer Total Market Share (%) Distribution in 2020
• 4.2. T-Cell Blood Cancer Total Market Share (%) Distribution in 2034

5. T-Cell Blood Cancer: Disease Background and Overview

• 5.1. Introduction
• 5.2. Sign and Symptoms
• 5.3. Pathophysiology
• 5.4. Risk Factors
• 5.5. Diagnosis

6. Patient Journey

7. T-Cell Blood Cancer Epidemiology and Patient Population

• 7.1. Epidemiology Key Findings
• 7.2. Assumptions and Rationale: 7MM
• 7.3. Epidemiology Scenario: 7MM
  • 7.3.1. T-Cell Blood Cancer Epidemiology Scenario in the 7MM (2020-2034)
• 7.4. United States Epidemiology
  • 7.4.1. T-Cell Blood Cancer Epidemiology Scenario in the United States (2020-2034)
• 7.5. EU-5 Country-wise Epidemiology
  • 7.5.1. Germany Epidemiology
    • 7.5.1.1. T-Cell Blood Cancer Epidemiology Scenario in Germany (2020-2034)
  • 7.5.2. France Epidemiology
    • 7.5.2.1. T-Cell Blood Cancer Epidemiology Scenario in France (2020-2034)
  • 7.5.3. Italy Epidemiology
    • 7.5.3.1. T-Cell Blood Cancer Epidemiology Scenario in Italy (2020-2034)
  • 7.5.4. Spain Epidemiology
    • 7.5.4.1. T-Cell Blood Cancer Epidemiology Scenario in Spain (2020-2034)
  • 7.5.5. United Kingdom Epidemiology
    • 7.5.5.1. T-Cell Blood Cancer Epidemiology Scenario in the United Kingdom (2020-2034)
  • 7.5.6. Japan Epidemiology
    • 7.5.6.1. T-Cell Blood Cancer Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

• 8.1. T-Cell Blood Cancer Treatment and Management
• 8.2. T-Cell Blood Cancer Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of T-Cell Blood Cancer Treatment

11. Marketed Products

• 11.1. List of Marketed Products in the 7MM
• 11.2. Drug Name: Company Name
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Pivotal Clinical Trials
  • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

• 12.1. Key Cross
• 12.2. Drug Name: Company Name
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Product Profile

List to be continued in report

13. T-Cell Blood Cancer: Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. T-Cell Blood Cancer Market Size in 7MM
• 13.3. T-Cell Blood Cancer Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

• 15.1. United States: Market Size
  • 15.1.1. T-Cell Blood Cancer Total Market Size in the United States
  • 15.1.2. T-Cell Blood Cancer Market Size by Therapies in the United States
• 15.2. EU-5 countries: Market Size and Outlook
• 15.3. Germany Market Size
  • 15.3.1. T-Cell Blood Cancer Total Market Size in Germany
  • 15.3.2. T-Cell Blood Cancer Market Size by Therapies in Germany
• 15.4. France Market Size
  • 15.4.1. T-Cell Blood Cancer Total Market Size in France
  • 15.4.2. T-Cell Blood Cancer Market Size by Therapies in France
• 15.5. Italy Market Size
  • 15.5.1. T-Cell Blood Cancer Total Market Size in Italy
  • 15.5.2. T-Cell Blood Cancer Market Size by Therapies in Italy
• 15.6. Spain Market Size
  • 15.6.1. T-Cell Blood Cancer Total Market Size in Spain
  • 15.6.2. T-Cell Blood Cancer Market Size by Therapies in Spain
• 15.7. United Kingdom Market Size
  • 15.7.1. T-Cell Blood Cancer Total Market Size in the United Kingdom
  • 15.7.2. T-Cell Blood Cancer Market Size by Therapies in the United Kingdom
• 15.8. Japan Market Outlook
  • 15.8.1. Japan Market Size
  • 15.8.2. T-Cell Blood Cancer Total Market Size in Japan
  • 15.8.3. T-Cell Blood Cancer Market Size by Therapies in Japan

16. Access and Reimbursement Overview of T-Cell Blood Cancer

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

• 20.1. Bibliography
• 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.

관련자료